2022年7月19日

图像/ Anastasiia Slynko实验室自动化球员MegaRobo偷了显示6月在亚太地区大型系列C轮3亿美元。肿瘤学Doma生物制药公司和泰疗法也导致私营生物技术投资排名。中国实验室自动化开发MegaRobo决定性的6月在亚太地区的生物技术投资。北京公司在一轮,将基金募集了3亿美元的扩张其技术新尺度和地理位置。MegaRobo的目标是提高效率的生命科学研究通过使用人工智能(AI)和机器人自动化许多研究技术包括抗体选择、细胞系发展和分子的筛选。“全球生命科学自动化行业拥有巨大的增长潜力,”凯文·丁,高盛资产管理公司执行董事,这是一个主要的投资者。“我们预计自动化解决方案的快速渗透继续挑战之际扩大生产、增加招聘的研发人才。“MegaRobo顶级轮击败可能在亚太地区最大的生物技术投资,这是一个系列的价值1亿美元的袋装Reistone生物制药在中国。6月排在第二位,Doma生物制药拿回家1.42亿美元资金研究一系列药物在其管道包括抗体药物配合和溶瘤病毒治疗。继续下面的内容相关内容提出的另一个显著的圆是InSilico药。 The company, based in Hong Kong and New York, is using a $60 million Series D financing to fund its pipeline of AI-designed drugs to treat diseases including fibrosis and inflammatory bowel disease. In addition to Doma Biopharmaceutical, the Singapore firm Tessa Therapeutics dominated the Series A arena. Flush with a $126 million investment, the startup is developing cell therapies for the treatment of both solid and blood cancer. The cell therapies resemble approved CAR-T cell therapies and involve modifying immune T cells from either the patient or a healthy donor to hunt down cancer cells. Imuneel Therapeutics, which raised a healthy $15 million biotech investment , is also developing a CAR-T therapy in India. In a similar fashion to InSilico, the Chinese AI player Helixon unveiled a large financing round bankrolling drug discovery technology that can speed up the development of large molecule drugs. This trend also follows a wave of investments in European AI drug discovery firms in J u ne like Charm Therapeutics and Relation Therapeutics. There were few seed-stage biotech investments in June in the Asia-Pacific region. One example is the Beijing-based Jingda Biotechnology Co., which is developing a cancer cell therapy that uses a type of immune cells called natural killer cells. Industrial biotechnology firms also were present in the mix in June, albeit with fewer big rounds than in healthcare. The biggest of these went to Mojia Biotech in China, which raised $80M to commercialize its animal feed additives that are designed to be produced more sustainably than currently available alternatives. Another notable round went to the Hong-Kong-based Avant Meats, which claims to be the first cultured meat in the region to be developing cultured fish meat. The startup raised a $10.8 million Series A round to help it make a sustainable, cell-based alternative to wild-caught and farmed fish. Content continues below